ClinicalTrials.gg

Program

vapendavir

Also written as “Vapendavir”, “VPV 1000 mg” and “vapendavir 132 mg capsule”.

Its studies are mostly in Enterovirus Infections · Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Tract Infections, led by 3 companies.

Furthest: phase 2, since Oct 11, 202310 company-led studies, 1 open or runningNext primary completion: Nov 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Altesa Biosciences41 open or runningphase 2since Oct 11, 2023Jun 7, 2023Nov 15, 2027phase 2 · NCT07610395
Vaxart40 open or runningphase 2since Feb 13, 2015Mar 24, 2014none ahead
Biota Scientific Management Pty20 open or runningphase 2since Aug 3, 2010Aug 3, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2010First study: phase 2 study in RhinovirusNew to Biota Scientific Management PtyBiota Scientific Management Pty · NCT01175226 · 300 enrolled · United States
  2. Mar 24, 2014Vaxart's first study: phase 1 study in HealthyNew to VaxartVaxart · NCT02101866 · 36 enrolled · United States
  3. May 27, 2014Phase 1 study in Drug-Drug Interaction Healthy VolunteersBiota Scientific Management Pty · NCT02204501 · 24 enrolled · United States
  4. Feb 13, 2015Phase 2 study in AsthmaVaxart · NCT02367313 · 455 enrolled · United States, Bulgaria, Czechia and more
  5. Aug 15, 2016Phase 1 study in HealthyVaxart · NCT02877264 · 48 enrolled · United States
  6. Jan 12, 2017Phase 2 study in Respiratory Tract InfectionsVaxart · NCT03024177
  7. Jun 7, 2023Altesa Biosciences's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Altesa BiosciencesAltesa Biosciences · NCT05962645 · 21 enrolled · United States
  8. Oct 11, 2023Phase 2 study in Virus DiseasesAltesa Biosciences · NCT06149494 · 52 enrolled · United Kingdom
  9. Feb 11, 2025Phase 2 study in Healthy MalesAltesa Biosciences · NCT06834295 · 8 enrolled · United Kingdom
  10. May 12, 2026Phase 2 study in Rhinovirus InfectionAltesa Biosciences · NCT07610395 · 180 planned · United States, United Kingdom

Ahead

  1. Nov 15, 2027Primary completion: phase 2 study in Rhinovirus InfectionAltesa Biosciences · NCT07610395

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“VP1 capsid protein inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07610395Rhinovirus Infection · United States, United Kingdom2RecruitingAltesa BiosciencesNov 15, 2027180
NCT06834295Healthy Males · United Kingdom2CompletedAltesa BiosciencesMar 23, 20258
NCT06149494Virus Diseases · United Kingdom2CompletedAltesa BiosciencesMar 30, 202552
NCT05962645Pulmonary Disease, Chronic Obstructive · United States1CompletedAltesa BiosciencesDec 12, 202321
NCT03024177Respiratory Tract Infections2WithdrawnVaxartApr 20170
NCT02877264Healthy · United States1CompletedVaxartAug 201648
NCT02367313Asthma · United States, Bulgaria, Czechia and more2CompletedVaxartDec 2016455
NCT02204501Drug-Drug Interaction Healthy Volunteers · United States1CompletedBiota Scientific Management PtyJun 201424
NCT02101866Healthy · United States1CompletedVaxartMay 201436
NCT01175226Rhinovirus · United States2CompletedBiota Scientific Management PtyMar 2012300

How it is read

Names in the registry

  • “Vapendavir”, 6 entries
  • “VPV 1000 mg”, 1 entry
  • “vapendavir 132 mg capsule”, 1 entry
  • “vapendavir 264 mg tablet”, 1 entry
  • “vapendavir 24 mg/mL oral suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.